Project Grant R01CA311928
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $640K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year research initiative investigates the molecular mechanisms by which the KEAP1-NRF2 redox-sensing pathway regulates CD8 T cell adaptation to chronic antigen receptor signaling in cancer and chronic infection contexts. The research...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas Southwestern Medical Center a Project Grant of $426,828 under the Cancer Treatment Research program (CFDA 93.395) on May 4, 2026, with a completion date of April 30, 2028. This research grant supports the validation and translation of findings regarding JUMONJI KDM5 histone demethylase enzymes and their role in mediating resistance to CDK4/6 inhibitors in estrogen receptor-positive (ER+) breast...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $627,371 project grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded on June 23, 2025, with an expected completion date of May 31, 2030. This award supports research focused on overcoming treatment resistance in estrogen receptor-positive (ER+) breast cancer through targeted degradation of cyclin-dependent kinases 4 and 6 (CDK4/6). The...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $596,501 to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) on June 20, 2026, with completion targeted for May 31, 2031. This award funds fundamental research investigating the molecular mechanisms of translocation renal cell carcinoma (TRCC), a particularly aggressive kidney cancer subtype that predominantly affects children and adolescents and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $473,372 Project Grant (CFDA 93.396 - Cancer Biology Research) to The University of Texas MD Anderson Cancer Center on April 8, 2026, through March 31, 2031. This award funds fundamental research investigating proline transfer RNA (tRNA) biogenesis as an oncogenic driver and potential therapeutic target in T cell acute lymphoblastic leukemia (T-ALL). The research addresses a critical knowledge gap regarding mechanisms...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $396,377 Project Grant to the University of Texas at Austin on May 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct comprehensive research characterizing mutational signatures at hotspots of genetic instability in human cancer genomes. The research deliverables include computational analysis of non-B DNA structures (including G-quadruplexes, Z-DNA, hairpins, and related...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...